JP6752276B2 - 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 - Google Patents

眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 Download PDF

Info

Publication number
JP6752276B2
JP6752276B2 JP2018520045A JP2018520045A JP6752276B2 JP 6752276 B2 JP6752276 B2 JP 6752276B2 JP 2018520045 A JP2018520045 A JP 2018520045A JP 2018520045 A JP2018520045 A JP 2018520045A JP 6752276 B2 JP6752276 B2 JP 6752276B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
eye
pharmaceutically acceptable
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018520045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521126A (ja
JP2018521126A5 (enExample
Inventor
アキム ハンス−ピーター クラウス
アキム ハンス−ピーター クラウス
Original Assignee
アクセロビジョン インコーポレイテッド
アクセロビジョン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセロビジョン インコーポレイテッド, アクセロビジョン インコーポレイテッド filed Critical アクセロビジョン インコーポレイテッド
Publication of JP2018521126A publication Critical patent/JP2018521126A/ja
Publication of JP2018521126A5 publication Critical patent/JP2018521126A5/ja
Application granted granted Critical
Publication of JP6752276B2 publication Critical patent/JP6752276B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018520045A 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 Expired - Fee Related JP6752276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020068158A Division JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物

Publications (3)

Publication Number Publication Date
JP2018521126A JP2018521126A (ja) 2018-08-02
JP2018521126A5 JP2018521126A5 (enExample) 2019-08-15
JP6752276B2 true JP6752276B2 (ja) 2020-09-09

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520045A Expired - Fee Related JP6752276B2 (ja) 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物
JP2020068158A Pending JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020068158A Pending JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物

Country Status (21)

Country Link
US (3) US10413535B2 (enExample)
EP (1) EP3319639B1 (enExample)
JP (2) JP6752276B2 (enExample)
KR (2) KR102440162B1 (enExample)
CN (1) CN107921136A (enExample)
AU (1) AU2016290197B2 (enExample)
BR (1) BR112018000112A2 (enExample)
CA (1) CA2989522C (enExample)
CL (1) CL2018000057A1 (enExample)
ES (1) ES2835274T3 (enExample)
HK (1) HK1247120A1 (enExample)
IL (2) IL256770B (enExample)
MA (2) MA42016A1 (enExample)
MX (1) MX385229B (enExample)
MY (1) MY187552A (enExample)
PL (1) PL3319639T3 (enExample)
RU (1) RU2018103940A (enExample)
TN (1) TN2017000538A1 (enExample)
UA (1) UA123728C2 (enExample)
WO (1) WO2017006272A1 (enExample)
ZA (1) ZA201708601B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592334A4 (en) * 2017-03-09 2020-12-16 Allysta Pharmaceuticals, Inc. PEPTIDES FOR DRY ILLNESS
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CA3145870A1 (en) * 2019-07-26 2021-02-04 Hampar L. Karageozian Peptides for treating non-exudative macular degeneration and other disorders of the eye
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
ES2530780T3 (es) * 2005-05-17 2015-03-05 Sarcode Bioscience Inc Composiciones y métodos para el tratamiento de trastornos oculares
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
MX385229B (es) 2025-03-14
US20180200240A1 (en) 2018-07-19
PL3319639T3 (pl) 2021-03-08
KR20180041122A (ko) 2018-04-23
WO2017006272A1 (en) 2017-01-12
US20200405703A1 (en) 2020-12-31
IL280827A (en) 2021-04-29
BR112018000112A2 (pt) 2018-09-04
TN2017000538A1 (en) 2019-04-12
CA2989522A1 (en) 2017-01-12
RU2018103940A (ru) 2019-08-08
EP3319639A1 (en) 2018-05-16
KR20220062688A (ko) 2022-05-17
ZA201708601B (en) 2019-05-29
ES2835274T3 (es) 2021-06-22
MA42016A1 (fr) 2018-03-30
HK1247120A1 (zh) 2018-09-21
JP2018521126A (ja) 2018-08-02
US10413535B2 (en) 2019-09-17
AU2016290197A1 (en) 2018-01-04
IL256770B (en) 2021-02-28
US20200000786A1 (en) 2020-01-02
IL256770A (en) 2018-03-29
CN107921136A (zh) 2018-04-17
KR102440162B1 (ko) 2022-09-02
US10751334B2 (en) 2020-08-25
MA44935A1 (fr) 2019-08-30
AU2016290197B2 (en) 2021-07-22
CL2018000057A1 (es) 2018-06-22
JP2020121985A (ja) 2020-08-13
CA2989522C (en) 2022-10-18
MY187552A (en) 2021-09-29
EP3319639B1 (en) 2020-11-18
RU2018103940A3 (enExample) 2019-09-03
UA123728C2 (uk) 2021-05-26
MX2017017163A (es) 2018-08-09

Similar Documents

Publication Publication Date Title
JP6752276B2 (ja) 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物
AU2021218212B2 (en) Compositions and methods for treating pterygium
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
Shah et al. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy
US12357565B2 (en) Ocular implant containing a tyrosine kinase inhibitor
BR112014027296B1 (pt) Nanopartículas farmacêuticas mostrando transporte mucosal melhorado
CN115066232B (zh) 用于治疗眼病的组合物和方法
KR20230097020A (ko) 활성제를 함유하는 안구 임플란트
US20170014487A1 (en) Method for treating ocular inflammation
US20220040166A1 (en) Methods and Compositions of Treating an Ophthalmic Condition
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.
US20250367130A1 (en) Thermoresponsive hydrogel containing metal-organic framework particles for noninvasive ocular drug delivery
Dumitrache Ophthalmological Pathology and Management in Eye Diseases: Uvea
CA2988293C (en) Compositions and methods for treating pterygium
US20190105194A1 (en) Methods of treating a subject with an ocular condition responsive to steroid therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200818

R150 Certificate of patent or registration of utility model

Ref document number: 6752276

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees